Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||unspecified CTLA4 antibody + unspecified PD-1 antibody|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|unspecified CTLA4 antibody||experimental CTLA4 antibody||Immune Checkpoint Inhibitor 135|
|unspecified PD-1 antibody||Experimental PD-1 antibody||Immune Checkpoint Inhibitor 135 PD-L1/PD-1 antibody 79|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PBRM1 loss||melanoma||sensitive||unspecified CTLA4 antibody + unspecified PD-1 antibody||Preclinical - Cell line xenograft||Actionable||In a preclinical study, knocking-out PBRM1 in melanoma cells sensitized cells to immune therapy consisted of anti-CTLA4 and anti-PD-1 antibodies in culture and in cell line xenograft models, potentially due to increased sensitivity to T cell-mediated cytotoxicity and a favorable tumor microenvironment (PMID: 29301958).||29301958|
|CTNNB1 act mut||hepatocellular carcinoma||decreased response||unspecified CTLA4 antibody + unspecified PD-1 antibody||Clinical Study - Cohort||Actionable||In a clinical study, treatment with immune checkpoint antibodies, including anti-PD-1, anti-PD-L1, or anti-CTLA-4 monotherapy or combinations of anti-PD-1 with anti-CTLA-4, anti-LAG3, or anti-KIR, was less effective in patients with Wnt pathway mutations in CTNNB1 or AXIN1 compared to patients without mutations in this pathway, with 0% (0/10) vs. 53% (9/17) achieving disease control, respectively, and shorter progression-free survival (2.0 months vs. 7.4 months) (PMID: 30373752; NCT01775072).||30373752|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|